Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Ebola Vaccine Passes Phase I Test

publication date: Mar 26, 2015
A China Ebola vaccine developed by Beijing Institute of Biotechnology and Tianjin CanSino Biotechnology completed a successful Phase I trial in Jiangsu, with results published in The Lancet. The vaccine is the first candidate tested that was developed to fight the current 2014 Zaire Guinea Ebola strain of the virus. The candidate was safe and provoked an immune response, though it still needs to prove that it can protect against the virus. The vaccine is delivered by a virus-like structure. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital